For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations and those who did not experience exacerbations. Higher health care ...

Medications for myasthenia gravis (MG) can include cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, and antibody fragment medications. While myasthenia gravis ...

Myasthenia gravis (MG) does not have stages but classes. These classes describe the muscles the condition affects and the severity of muscle weakness, which can influence the treatments a doctor ...

Background Early fast-acting treatment (EFT) is the aggressive use of fast-acting therapies such as plasmapheresis, intravenous immunoglobulin and/or intravenous ... or better status with ≤5 mg/day ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Myasthenia gravis is an ...

Department of Neurological Sciences, Robert Larner MD College of Medicine, University of Vermont and the University of Vermont Medical Center, Burlington, VT 05401, USA ...

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will present its ...

Alyx is designed to help optimize your bottom line with reduced labor and error related costs and the ability to increase collection of high value components.

Therapeutic plasmapheresis is currently used to treat neurological disorders such as Guillain-Barre syndrome, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and autoimmune ...